Cargando…
Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients
PURPOSE: Vaccines against COVID-19 have a lower efficacy in HT patients (pts); factors influencing their immunogenicity are unknown. The aim of this study is to investigate the role of immunosuppression on mRNA vaccines efficacy. METHODS: We included all HT pts followed in our Center completing the...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988650/ http://dx.doi.org/10.1016/j.healun.2022.01.419 |
_version_ | 1784683009763442688 |
---|---|
author | Masetti, M. Aloisio, A. Giovannini, L. Borgese, L. Caroccia, N. Pascale, R. Lazzarotto, T. Giannella, M. Pacini, D. Viale, P. Potena, L. |
author_facet | Masetti, M. Aloisio, A. Giovannini, L. Borgese, L. Caroccia, N. Pascale, R. Lazzarotto, T. Giannella, M. Pacini, D. Viale, P. Potena, L. |
author_sort | Masetti, M. |
collection | PubMed |
description | PURPOSE: Vaccines against COVID-19 have a lower efficacy in HT patients (pts); factors influencing their immunogenicity are unknown. The aim of this study is to investigate the role of immunosuppression on mRNA vaccines efficacy. METHODS: We included all HT pts followed in our Center completing the vaccine cycle (03-06/21), for whom levels of IgG anti-RBD after the second dose were known, excluding those with a previous COVID infection. Demography, immunosuppression (drugs and trough blood level), lymphocyte count, previous rejection episodes were collected before the first dose. The endpoint was vaccine-induced immunization after the second dose according to our laboratory's threshold of IgG anti-RBD. RESULTS: Among 201 vaccinated, IgG anti-RBD values were available for 63 pts at 2± 1 months after the second dose (22±3 days after the first; 89% BNT162b2; 60±11 yrs, 5±1 yrs from HT, 75% males, 3 with rejection > 1R in the previous 6 months). All pts were on CNI-inhibitors (35% tacrolimus, TAC, 65% cyclosporine, CyA), 57% on MMF, 23% mTOR, 69% steroids (CS). 41.7% had no response to vaccine. At univariate analysis the predictors of lack of response to vaccine were: MMF (43% vs 71%), TAC vs CSA (27% vs 73%), steroids (46% vs 76%), steroid dose > 5mg, lymphocytes <18% of leukocytes (both identified by ROC), more than 5 years from HT; mTOR was more likely associated with protection (80% vs 49%), p<0.05 all. Importantly, age was not predictive of immunogenicity. At stepwise multivariate analysis all these factors maintained statistical significance (p<0.05 all). IgG anti-RBD values were influenced by low lymphocytes, steroids and TAC trough levels (p< 0.05 all).Response to vaccine was the lowest for MMF+TAC+CS (23.1%), intermediate for MMF+CyA+CS (53.3%) and steroid-free regimens (68.7%), highest (87.5%) for mTOR+CNI+CS (20%,23%,24%,23% of pts, p=0.01). No rejection episodes were registered 3 months after the second dose of vaccine. CONCLUSION: While confirming a low response to COVID-19 vaccines a in HT pts, our study underscores the negative effect of immunosuppression, particularly of MMF, high doses of steroids and TAC. Given that MMF is a cornerstone of most protocols, from these results it arises the hypothesis (to be tested in larger studies) if switching stable patients from TAC to Cya or to lower steroid doses may favor the attempts to increase the response to vaccines. |
format | Online Article Text |
id | pubmed-8988650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89886502022-04-11 Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients Masetti, M. Aloisio, A. Giovannini, L. Borgese, L. Caroccia, N. Pascale, R. Lazzarotto, T. Giannella, M. Pacini, D. Viale, P. Potena, L. J Heart Lung Transplant (398) PURPOSE: Vaccines against COVID-19 have a lower efficacy in HT patients (pts); factors influencing their immunogenicity are unknown. The aim of this study is to investigate the role of immunosuppression on mRNA vaccines efficacy. METHODS: We included all HT pts followed in our Center completing the vaccine cycle (03-06/21), for whom levels of IgG anti-RBD after the second dose were known, excluding those with a previous COVID infection. Demography, immunosuppression (drugs and trough blood level), lymphocyte count, previous rejection episodes were collected before the first dose. The endpoint was vaccine-induced immunization after the second dose according to our laboratory's threshold of IgG anti-RBD. RESULTS: Among 201 vaccinated, IgG anti-RBD values were available for 63 pts at 2± 1 months after the second dose (22±3 days after the first; 89% BNT162b2; 60±11 yrs, 5±1 yrs from HT, 75% males, 3 with rejection > 1R in the previous 6 months). All pts were on CNI-inhibitors (35% tacrolimus, TAC, 65% cyclosporine, CyA), 57% on MMF, 23% mTOR, 69% steroids (CS). 41.7% had no response to vaccine. At univariate analysis the predictors of lack of response to vaccine were: MMF (43% vs 71%), TAC vs CSA (27% vs 73%), steroids (46% vs 76%), steroid dose > 5mg, lymphocytes <18% of leukocytes (both identified by ROC), more than 5 years from HT; mTOR was more likely associated with protection (80% vs 49%), p<0.05 all. Importantly, age was not predictive of immunogenicity. At stepwise multivariate analysis all these factors maintained statistical significance (p<0.05 all). IgG anti-RBD values were influenced by low lymphocytes, steroids and TAC trough levels (p< 0.05 all).Response to vaccine was the lowest for MMF+TAC+CS (23.1%), intermediate for MMF+CyA+CS (53.3%) and steroid-free regimens (68.7%), highest (87.5%) for mTOR+CNI+CS (20%,23%,24%,23% of pts, p=0.01). No rejection episodes were registered 3 months after the second dose of vaccine. CONCLUSION: While confirming a low response to COVID-19 vaccines a in HT pts, our study underscores the negative effect of immunosuppression, particularly of MMF, high doses of steroids and TAC. Given that MMF is a cornerstone of most protocols, from these results it arises the hypothesis (to be tested in larger studies) if switching stable patients from TAC to Cya or to lower steroid doses may favor the attempts to increase the response to vaccines. Published by Elsevier Inc. 2022-04 2022-04-07 /pmc/articles/PMC8988650/ http://dx.doi.org/10.1016/j.healun.2022.01.419 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | (398) Masetti, M. Aloisio, A. Giovannini, L. Borgese, L. Caroccia, N. Pascale, R. Lazzarotto, T. Giannella, M. Pacini, D. Viale, P. Potena, L. Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title | Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title_full | Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title_fullStr | Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title_full_unstemmed | Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title_short | Role of Immunosuppression on Efficacy of Anti-SARS-CoV-2 Vaccines in Heart Transplanted (HT) Patients |
title_sort | role of immunosuppression on efficacy of anti-sars-cov-2 vaccines in heart transplanted (ht) patients |
topic | (398) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988650/ http://dx.doi.org/10.1016/j.healun.2022.01.419 |
work_keys_str_mv | AT masettim roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT aloisioa roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT giovanninil roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT borgesel roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT caroccian roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT pascaler roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT lazzarottot roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT giannellam roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT pacinid roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT vialep roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients AT potenal roleofimmunosuppressiononefficacyofantisarscov2vaccinesinhearttransplantedhtpatients |